⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2047080 | 0.96 | — | — | |
| SCHEMBL9956415 | 0.90 | KMT2A (0.36) | — | |
| SCHEMBL7992221 | 0.90 | KMT2A (0.36) | — | |
| SCHEMBL7737845 | 0.90 | KMT2A (0.36) | — | |
| SCHEMBL542776 | 0.90 | KMT2A (0.36) | — | |
| SCHEMBL25327994 | 0.90 | KMT2A (0.36) | — | |
| SCHEMBL7340365 | 0.90 | KMT2A (0.36) | — | |
| SCHEMBL13858690 | 0.90 | KMT2A (0.36) | — | |
| SCHEMBL61394 | 0.90 | KMT2A (0.36) | — | |
| SCHEMBL11594630 | 0.90 | KMT2A (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4347597-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | claimed |
| CN-117377674-A | Pyrazolo [1,5-a ] pyrimidine compounds for the treatment of dermatological disorders | 大塚制药株式会社 | 2024-01-09 | — | — | CN | claimed |
| WO-2022255408-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-12-08 | — | — | WO | claimed |
| CN-109195966-B | Microbiocidal thiazole derivatives | 先正达参股股份有限公司 | 2022-09-16 | — | — | CN | claimed |
| CN-103443099-B | Regulate composition and the method for FXR | NOVARTIS AG (CH) | 2016-03-23 | — | — | CN | claimed |
| CN-103443099-A | Compositions and methods for modulating FXR | IRM LLC | 2013-12-11 | — | — | CN | claimed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| CN-113874353-B | Microbiocidal derivatives | 先正达农作物保护股份公司 | 2024-06-14 | — | — | CN | disclosed |
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| EP-4347597-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUND FOR THE TREATMENT OF DERMAL DISORDERS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-117377674-A | Pyrazolo [1,5-a ] pyrimidine compounds for the treatment of dermatological disorders | 大塚制药株式会社 | 2024-01-09 | — | — | CN | disclosed |
| CN-111592534-B | New compounds | 特殊治疗有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230058189-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. (US) | 2023-02-23 | — | — | US | disclosed |
| CN-101035540-A | Pharmaceutical combinations containing benzoxazine for treating respiratory diseases | BOEHRINGER INGELHEIM INT (DE) | 2007-09-12 | — | — | CN | disclosed |
| CN-1305853-C | Process for the preparation of HMG-CoA reductase inhibitors | NOVARTIS AG (CH) | 2007-03-21 | — | — | CN | disclosed |
| WO-2006119400-A2 | SUBSTITUTED 4,5-DIHYDRO-1,2,4-TRIAZIN-6-ONES, 1,2,4-TRIANZIN-6-ONES, AND THEIR USE AS FUNGICIDES | DOW AGROSCIENCES LLC (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060252755-A1 | Substituted 4,5-dihydro-1,2,4-triazin-6-ones, 1,2,4-triazin-6-ones, and their use as fungicides | DOW AGROSCIENCES LLC | 2006-11-09 | — | — | US | disclosed |
| CN-1622937-A | Process for the manufacture of HMG-coa reductase inhibitors | NOVARTIS AG (CH) | 2005-06-01 | — | — | CN | disclosed |
| US-5364871-A | Antiulcer agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-11-15 | — | — | US | disclosed |